Arcus Biosciences Inc (RCUS) Stock Price, Quote & News

Company Profile

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 694 6200

Website: www.arcusbio.com

Address:

3928 Point Eden Way, Hayward, United States

Bobes Oct. 24 at 12:50 AM

$RCUS we lost 2 watchers on st over the past two days. Bummer

1 · Reply

IceJuice Oct. 22 at 3:50 PM

$RCUS 3rd week in a row ……

0 · Reply

ACES_ Oct. 22 at 2:53 PM

$RCUS more games - calls are not budging- Mother fuckers

0 · Reply

wetsalmon Oct. 22 at 9:15 AM

$RCUS Straddle or synthetic long?

1 · Reply

Mountaineer96 Oct. 21 at 7:58 PM

$RCUS four new followers today we are really getting popular and the word is out now. BUY BUY BUY

0 · Reply

MRTunity Oct. 21 at 7:06 PM

$RCUS this stock has been the exact opposite of $SLS for me - barely any one here talking about it! Few who do all seem level headed and got their wits about them, not a circus 🤡 like other threads and stock never has any CRAZY DAY, but slow and steady she goes … endlessly hitting higher highs and higher lows… don’t get too excited until zoom out and realize holy shit I’m up 💯 in this just the last 3 months wow 🤩

0 · Reply

MRTunity Oct. 21 at 6:52 PM

$RCUS 🤑 thanks to @TheGunnerAB on this one for those $2 Dec19 he pointed to! While I did take a hit on those July18 that expired worthless , I’m up 200% PLUS on these Dec ones I’m sure be over $10+ come Expiration

1 · Reply

tradingjunk321 Oct. 21 at 5:40 PM

$RCUS 🤫

1 · Reply

Jellysquid1 Oct. 20 at 4:54 PM

$RCUS Let’s keep Rcus Going UPWARD! Cmon Gilead buy The whole Company Already!!!

0 · Reply

JarvisFlow Oct. 20 at 1:38 PM

Wells Fargo has adjusted their stance on Arcus Biosciences ( $RCUS ), setting the rating to Overweight with a target price of 25 → 29.

0 · Reply

Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia

Oct 16, 2025, 11:18 AM EDT - 9 days ago

Arcus Biosciences: Refusing To Let The TIGIT Story Die, And Finding Potential Niches In Huge Markets

Oct 12, 2025, 6:05 PM EDT - 12 days ago

Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study

Oct 9, 2025, 4:35 PM EDT - 16 days ago

Arcus Biosciences Announces New Employment Inducement Grants

Oct 6, 2025, 11:15 PM EDT - 18 days ago

Arcus Biosciences, Inc. (RCUS) Shareholder/Analyst Call Transcript

Oct 6, 2025, 2:23 PM EDT - 19 days ago

Why Is Arcus Biosciences Stock Trading Higher On Monday?

Oct 6, 2025, 8:00 AM EDT - 19 days ago

Arcus Biosciences Presents New Data for its HIF-2a Inhibitor Casdatifan and Discloses First Inflammation Programs at Investor Event

Sep 10, 2025, 11:59 AM EDT - 6 weeks ago

Arcus Biosciences, Inc. (RCUS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 3, 2025, 5:08 PM EDT - 7 weeks ago

Arcus Biosciences, Inc. (RCUS) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 2, 2025, 4:05 PM EDT - 7 weeks ago

Arcus Biosciences to Host Investor Event to Highlight its Late-Stage Casdatifan Program and Next Wave of Programs Focused on Inflammation

Aug 20, 2025, 4:05 PM EDT - 2 months ago

Arcus Biosciences to Participate in Three Upcoming Investor Conferences

Aug 14, 2025, 8:07 AM EDT - 2 months ago

Jim Cramer Recommends This Energy Stock, But Don't 'Bank It All' On Arcus

UEC

Aug 10, 2025, 9:34 AM EDT - 2 months ago

Arcus Biosciences: A Risky Buy Ahead Of Pivotal, Catalyst-Rich 12 Months

Aug 6, 2025, 4:05 PM EDT - 2 months ago

Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update

Jul 10, 2025, 8:30 AM EDT - 3 months ago

Arcus Biosciences' Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer

Jun 1, 2025, 10:45 AM EDT - 5 months ago

Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response

May 6, 2025, 8:17 PM EDT - 6 months ago

Arcus Biosciences, Inc. (RCUS) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:05 PM EDT - 6 months ago

Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update

Apr 23, 2025, 4:05 PM EDT - 6 months ago

Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting

Apr 22, 2025, 4:05 PM EDT - 6 months ago

Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update

Apr 2, 2025, 3:48 PM EDT - 7 months ago

Arcus Biosciences: A High-Risk Speculation With Multiple Large, Near-Term Catalysts

Feb 26, 2025, 4:35 PM EST - 8 months ago

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

Feb 25, 2025, 4:05 PM EST - 8 months ago

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update

Feb 18, 2025, 6:57 AM EST - 8 months ago

Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering

Feb 18, 2025, 6:52 AM EST - 8 months ago

Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock

Feb 15, 2025, 3:45 PM EST - 8 months ago

New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer

Feb 10, 2025, 5:00 PM EST - 9 months ago

Arcus Biosciences to Present New Data from Casdatifan, a HIF-2a Inhibitor, in an Oral Presentation at the 2025 ASCO GU Symposium

Jan 21, 2025, 4:05 PM EST - 9 months ago

Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer

Jan 14, 2025, 10:51 PM EST - 10 months ago

Arcus Biosciences: Many Important Oncology Catalysts Coming Up In 2025

Jan 13, 2025, 8:00 AM EST - 10 months ago

Arcus: Excellent Pipeline And Collaborations, Cash Runway

Dec 19, 2024, 4:05 PM EST - 11 months ago

Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Nov 6, 2024, 11:39 PM EST - 1 year ago

Arcus Biosciences, Inc. (RCUS) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:22 PM EST - 1 year ago

Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update

Nov 5, 2024, 9:00 AM EST - 1 year ago

Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer

Oct 30, 2024, 9:00 AM EDT - 1 year ago

Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting

Oct 24, 2024, 7:30 AM EDT - 1 year ago

First Clinical Data for Arcus Biosciences' HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer

Oct 22, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update

Oct 9, 2024, 8:00 AM EDT - 1 year ago

Arcus Biosciences to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium

Oct 2, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma

AZN

Sep 23, 2024, 1:53 AM EDT - 1 year ago

Arcus Biosciences Looks Compelling Ahead Of Key Clinical Oncology Milestones

Aug 27, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences Secures Up to $250 Million Term Loan Facility from Hercules Capital

HTGC

Aug 9, 2024, 5:31 PM EDT - 1 year ago

Arcus Biosciences: Getting Too Cheap To Ignore (Reiterate Buy)

Aug 9, 2024, 5:21 PM EDT - 1 year ago

Arcus Biosciences, Inc. (RCUS) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences Reports Second-Quarter 2024 Financial Results and Provides a Pipeline Update

Jul 25, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2024 Financial Results and Pipeline Update

Jul 8, 2024, 6:00 PM EDT - 1 year ago

Taiho Pharmaceutical Exercises Option for an Exclusive License to Quemliclustat in Japan and Certain Territories in Asia

Jun 10, 2024, 8:30 AM EDT - 1 year ago

Arcus Biosciences Completes Patient Enrollment in Phase 3 Trial Evaluating a Domvanalimab-Containing Regimen in First-Line Metastatic Upper GI Cancers

Jun 6, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 2, 2024, 8:00 AM EDT - 1 year ago

Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer

GILD

Jun 1, 2024, 8:00 AM EDT - 1 year ago

Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers

GILD

Bobes Oct. 24 at 12:50 AM

$RCUS we lost 2 watchers on st over the past two days. Bummer

1 · Reply

IceJuice Oct. 22 at 3:50 PM

$RCUS 3rd week in a row ……

0 · Reply

ACES_ Oct. 22 at 2:53 PM

$RCUS more games - calls are not budging- Mother fuckers

0 · Reply

wetsalmon Oct. 22 at 9:15 AM

$RCUS Straddle or synthetic long?

1 · Reply

Mountaineer96 Oct. 21 at 7:58 PM

$RCUS four new followers today we are really getting popular and the word is out now. BUY BUY BUY

0 · Reply

MRTunity Oct. 21 at 7:06 PM

0 · Reply

MRTunity Oct. 21 at 6:52 PM

1 · Reply

tradingjunk321 Oct. 21 at 5:40 PM

$RCUS 🤫

1 · Reply

Jellysquid1 Oct. 20 at 4:54 PM

$RCUS Let’s keep Rcus Going UPWARD! Cmon Gilead buy The whole Company Already!!!

0 · Reply

JarvisFlow Oct. 20 at 1:38 PM

Wells Fargo has adjusted their stance on Arcus Biosciences ( $RCUS ), setting the rating to Overweight with a target price of 25 → 29.

0 · Reply

tradingjunk321 Oct. 19 at 11:07 PM

$RCUS anyone know the dollars involved, just saw this on X, this is today's news!

2 · Reply

ACES_ Oct. 18 at 12:33 PM

$RCUS https://x.com/arcusbio/status/1979517874315120797

1 · Reply

hashtagzee Oct. 18 at 12:38 AM

$AUPH $RCUS Boesky you made a tremendous call to scoop this up in the summer. Instead of 160K profit there, I made peanuts here with AUPHful. Fortunately I dumped some into UNH mid $200 range for a 30% return thus far.

1 · Reply

ACES_ Oct. 17 at 4:05 PM

$RCUS fuckin games... own it.. period. This should be 30 bucks ... at least.

0 · Reply

prestoncoleman33 Oct. 17 at 3:59 PM

$RCUS H1 2025 loss per share improved from negative 19.73 to negative 2.65, that is a real delta, combine with OPEX discipline down roughly 30 percent and you have the skeleton of a cash burn inflection when volumes lift

0 · Reply

Jellysquid1 Oct. 16 at 10:31 PM

$RCUS Lets get back on track! Rcus, lets keep going UPWARDS!

0 · Reply